Biotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector.
Concurrent with the merger, nChroma also completed a $75M financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners, with participation from 5AM Ventures, DCVC Bio, F-Prime Capital, GV (Google Ventures), Janus Henderson Investors, Mubadala Capital, Omega Funds, Sixth Street, Sofinnova Partners, T. Rowe Price, Wellington Management, Alexandria Venture Investments, Casdin Capital, Menlo Ventures and Wilson Sonsini Goodrich & Rosati.
The company intends to use the funds to drive the lead program to meaningful clinical data and to build a pipeline of hepatic and extrahepatic targeted therapies.
Led by CEO Jeff Walsh, nChroma Bio is a biotechnology company specializes in vivo targeted genetic medicine to treat a wide array of diseases and bring cures to patients. Its integrated product engine tackles significant limitations of existing genetic medicine approaches by enabling safe, precise and specific in vivo delivery. nChroma’s near clinical-stage development candidate, CRMA-1001, is a liver-targeted therapy in development as a potential functional cure for chronic hepatitis B and hepatitis D that leverages the power of epigenetics, nature’s innate mechanism for gene regulation.
Its leadership includes:
- Melissa Bonner, PhD, Chief Scientific Officer
- Noah Goodman, Chief Business Officer
- Padma Malyala, Senior Vice President, Technology Development
- Jenny Marlowe, PhD, Chief Development Officer
- Lisa McGrath, Chief People Officer
- Jeff Walsh, Chief Executive Officer
FinSMEs
12/12/2024